Formula Growth’s Moderna MRNA Stock Holding History

Formula Growth’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$749K	–	156
2020 Q1	$749K	Buy	+25,000	New	+$575K	0.14%	111

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Formula Growth's MRNA Position: Q2 2020 in Review

Formula Growth sold out of Moderna (MRNA) in Q2 2020, closing a stake of 25,000 shares — an estimated $749K sold.

Formula Growth first reported a position in MRNA in Q1 2020 and held it in 1 quarter. The position peaked at $749K in Q1 2020. 489 funds tracked by Wall St. Rank hold MRNA as of Q2 2020.

Formula Growth reported no remaining Moderna position as of Q2 2020 after selling out during the quarter.
Formula Growth sold 25,000 Moderna shares in Q2 2020, an estimated $749K.
Formula Growth first reported a position in Moderna in Q1 2020 and held it in 1 quarter.
Formula Growth's Moderna position peaked at $749K in Q1 2020.
489 funds tracked by Wall St. Rank held Moderna as of Q2 2020.

Based on Formula Growth's 13F filing for Q2 2020, filed 13 Aug 2020.